32. A pharmaceutical composition comprising the compound according any of claims 28-31, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or diluent.

33. ~~A method of treating a disease or condition that involves HSP90 comprising administering to an animal, in need of said treatment, the~~ Use of a compound according to any of claims 28-31, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a disease or condition that involves HSP90.

34. The ~~method~~ use according to claim 33, wherein the disease being treated is selected from breast cancer, CML, colorectal carcinoma, glioma, melanoma, multiple myeloma, non-small cell lung cancer, ovarian cancer, prostate cancer, renal cell carcinoma, small cell lung carcinoma, unfolded protein response, neurodegenerative disease, infectious disease, inflammatory disease, autoimmune disorder, stroke, ischemia, cardiac disorder, sepsis, fibrogenetic disorder, d metabolic disease, infection from negative strand RNA viruses, influenza virus, hepatitis B, hepatitis C, and herpes simplex virus type 1.